Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Ranibizumab is a potential prophylaxis for proliferative vitreoretinopathy, a nonangiogenic blinding disease.

Pennock S, Kim D, Mukai S, Kuhnle M, Chun DW, Matsubara J, Cui J, Ma P, Maberley D, Samad A, Van Geest RJ, Oberstein SL, Schlingemann RO, Kazlauskas A.

Am J Pathol. 2013 May;182(5):1659-70. doi: 10.1016/j.ajpath.2013.01.052. Epub 2013 Apr 9.

2.

Vascular endothelial growth factor acts primarily via platelet-derived growth factor receptor α to promote proliferative vitreoretinopathy.

Pennock S, Haddock LJ, Mukai S, Kazlauskas A.

Am J Pathol. 2014 Nov;184(11):3052-68. doi: 10.1016/j.ajpath.2014.07.026. Epub 2014 Sep 26.

3.

Recent developments in our understanding of how platelet-derived growth factor (PDGF) and its receptors contribute to proliferative vitreoretinopathy.

Lei H, Rheaume MA, Kazlauskas A.

Exp Eye Res. 2010 Mar;90(3):376-81. doi: 10.1016/j.exer.2009.11.003. Epub 2009 Nov 25. Review.

4.

Growth factors outside the PDGF family drive experimental PVR.

Lei H, Velez G, Hovland P, Hirose T, Gilbertson D, Kazlauskas A.

Invest Ophthalmol Vis Sci. 2009 Jul;50(7):3394-403. doi: 10.1167/iovs.08-3042. Epub 2009 Mar 25.

5.

Is neutralizing vitreal growth factors a viable strategy to prevent proliferative vitreoretinopathy?

Pennock S, Haddock LJ, Eliott D, Mukai S, Kazlauskas A.

Prog Retin Eye Res. 2014 May;40:16-34. doi: 10.1016/j.preteyeres.2013.12.006. Epub 2014 Jan 9. Review.

PMID:
24412519
6.

A potential role for PDGF-C in experimental and clinical proliferative vitreoretinopathy.

Lei H, Hovland P, Velez G, Haran A, Gilbertson D, Hirose T, Kazlauskas A.

Invest Ophthalmol Vis Sci. 2007 May;48(5):2335-42.

PMID:
17460299
7.

Plasmin is the major protease responsible for processing PDGF-C in the vitreous of patients with proliferative vitreoretinopathy.

Lei H, Velez G, Hovland P, Hirose T, Kazlauskas A.

Invest Ophthalmol Vis Sci. 2008 Jan;49(1):42-8. doi: 10.1167/iovs.07-0776.

8.

A novel function of p53: a gatekeeper of retinal detachment.

Lei H, Rheaume MA, Cui J, Mukai S, Maberley D, Samad A, Matsubara J, Kazlauskas A.

Am J Pathol. 2012 Sep;181(3):866-74. doi: 10.1016/j.ajpath.2012.05.036.

9.

A novel strategy to develop therapeutic approaches to prevent proliferative vitreoretinopathy.

Pennock S, Rheaume MA, Mukai S, Kazlauskas A.

Am J Pathol. 2011 Dec;179(6):2931-40. doi: 10.1016/j.ajpath.2011.08.043. Epub 2011 Oct 28.

11.

Attenuation of experimental proliferative vitreoretinopathy by inhibiting the platelet-derived growth factor receptor.

Ikuno Y, Leong FL, Kazlauskas A.

Invest Ophthalmol Vis Sci. 2000 Sep;41(10):3107-16.

PMID:
10967071
12.

Vitreous vascular endothelial growth factor concentrations in proliferative diabetic retinopathy versus proliferative vitreoretinopathy.

Citirik M, Kabatas EU, Batman C, Akin KO, Kabatas N.

Ophthalmic Res. 2012;47(1):7-12. doi: 10.1159/000324200. Epub 2011 Jun 21.

PMID:
21691136
13.

Balance of vascular endothelial growth factor and pigment epithelial growth factor prior to development of proliferative vitreoretinopathy.

Dieudonné SC, La Heij EC, Diederen RM, Kessels AG, Liem AT, Kijlstra A, Hendrikse F.

Ophthalmic Res. 2007;39(3):148-54. Epub 2007 May 25.

PMID:
17534114
14.

Platelet-derived growth factor receptor kinase inhibitor AG1295 and inhibition of experimental proliferative vitreoretinopathy.

Zheng Y, Ikuno Y, Ohj M, Kusaka S, Jiang R, Cekiç O, Sawa M, Tano Y.

Jpn J Ophthalmol. 2003 Mar-Apr;47(2):158-65.

PMID:
12738549
15.

Platelet-derived growth factor plays a key role in proliferative vitreoretinopathy.

Andrews A, Balciunaite E, Leong FL, Tallquist M, Soriano P, Refojo M, Kazlauskas A.

Invest Ophthalmol Vis Sci. 1999 Oct;40(11):2683-9.

PMID:
10509666
16.

Vitreous and serum levels of platelet-derived growth factor and their correlation in patients with proliferative diabetic retinopathy.

Praidou A, Klangas I, Papakonstantinou E, Androudi S, Georgiadis N, Karakiulakis G, Dimitrakos S.

Curr Eye Res. 2009 Feb;34(2):152-61. doi: 10.1080/02713680802585920.

PMID:
19219687
17.

Antiangiogenic isoforms of vascular endothelial growth factor predominate in subretinal fluid of patients with rhegmatogenous retinal detachment and proliferative vitreoretinopathy.

Ricker LJ, Dieudonné SC, Kessels AG, Rennel ES, Berendschot TT, Hendrikse F, Kijlstra A, La Heij EC.

Retina. 2012 Jan;32(1):54-9. doi: 10.1097/IAE.0b013e31821800b9.

PMID:
21836532
18.

N-acetylcysteine suppresses retinal detachment in an experimental model of proliferative vitreoretinopathy.

Lei H, Velez G, Cui J, Samad A, Maberley D, Matsubara J, Kazlauskas A.

Am J Pathol. 2010 Jul;177(1):132-40. doi: 10.2353/ajpath.2010.090604. Epub 2010 May 20.

20.

Expression of PDGFRα is a determinant of the PVR potential of ARPE19 cells.

Lei H, Rhéaume MA, Velez G, Mukai S, Kazlauskas A.

Invest Ophthalmol Vis Sci. 2011 Aug 24;52(9):5016-21. doi: 10.1167/iovs.11-7442.

Items per page

Supplemental Content

Write to the Help Desk